| Abstrakt: |
The University of Cincinnati Cancer Center presented research at the American Society for Radiation Oncology (ASTRO) Annual Meeting. One study focused on osteoradionecrosis (ORN), a condition where exposed bone fails to heal after radiation treatment for head and neck cancer. The researchers found higher rates of ORN in patients with oral cavity squamous cell carcinoma, especially in younger patients and those who underwent surgical removal of part or all of the jaw bones. Another study found that progesterone contraception, specifically the drug Provera, is a significant risk factor for vision loss in premenopausal women with meningiomas. The researchers are now testing patient samples to determine how many express the progesterone receptor. Lastly, researchers investigated the potential of combining a Plk1 inhibitor with radiation therapy for HPV-negative head and neck cancer. The combination therapy showed promise in reducing cell viability and tumor growth in HPV-negative cancer cells. [Extracted from the article] |
